Search

Zinc oxide nanoparticles (ZnONPs), characterized by their nanoscale dimensions and unique properties, have emerged as promising materials in various applications. From electronics to biomedicine, their versatility and biocompatibility makes them valuable assets to address multifaceted challenges. This study aimed to comparatively analyze chemically synthesized ZnONPs (CS-ZnONPs) and Illicium verum-mediated ZnONPs (IV-ZnONPs) in terms of characteristics and biological activities. Characterization of both types of synthesized ZnONPs were done by using various techniques namely XRD, UV-vis spectroscopy, FTIR, TEM, and EDX. TEM and XRD results revealed the variability in size and shape of IV-ZnONPs (∼13.75 nm; triangular) and CS-ZnONPs (∼38.9 nm; flower-shaped). FTIR spectra showed the presence of different phytochemicals present in I. verum extract involved in the capping of IV-ZnONPs. Both types of ZnONPs were found to be biocompatible in nature. Furthermore, variations in their biological properties were observed using different in vitro assays, such as FRAP (242.3 ± 18.9 and 101.5 ± 9.5 μM TEAC), CUPRAC (249.8 ± 8.9 and 149.5 ± 8.2 μM TEAC), ABTS (I36.2 ± 0.5 and 28.2 ± 0.8 μM TEAC), and ORAC cell-free assays (19.9 ± 0.6 and 11.9 ± 0.9 μM TEAC) for anti-oxidant investigations of IV-ZnONPs and CS-ZnONPs, respectively. Percentage Inhibition of Vespelysine-like AGEs and pentosidine-like AGEs for anti-aging analysis were reported. In addition to these, the anti-cancerous potential of both types of ZnONPs was also studied based on MTT assay, ROS/NOS production, mitochondria membrane potential, activity of caspase 3/7 measurements, and expression of caspase-3 gene in mammalian HepG2 cell lines. Our findings revealed that both types of ZnONPs were found to be more active through electron-transfer anti-oxidant mechanism. Likewise, the findings of anti-aging analyses revealed significant difference of inhibitory potential between CS-ZnONPs and IV-ZnONPs. As far as anti-cancerous potential is concerned, both IV-ZnONPs and CS-ZnONPs were found to have promising potential against HepG2 cells. However, CS-ZnONPs were observed to have a slight edge over IV-ZnONPs. Nonetheless, the overall results indicated that ZnONPs synthesized through the green route exhibit outstanding biological potential, positioning them as promising candidates for future biomedical applications, particularly in the realm of cancer therapeutics. [ABSTRACT FROM AUTHOR]

Topical corticosteroids (TCSs) are classified into four potencies: mild, moderate, potent and very potent. Confusion arises from the wide range of products available, none of which have the potency level printed on the tubes or packaging. An online survey of patients and carers of people with eczema showed that only 17% of 984 respondents knew how many potencies there are. In a second survey, 315 respondents provided 1520 assignments of the potency of commonly used TCSs: 55.5% were correct, 21% were underestimates and 23.5% overestimates. Some errors were extreme: 12 (8%) of those using a very potent TCS considered it mild while 9 (27%) using a mild TCS considered it potent or very potent. Other themes expressed in free-text comments included inadequate and conflicting advice about using TCSs and lack of warnings about long-term adverse effects, particularly topical steroid withdrawal. Ninety-five per cent of respondents wanted TCSs to be clearly labelled with potency. [ABSTRACT FROM AUTHOR]

Traditionally, Sezary syndrome (SS) has been associated with few therapeutic options and poor prognosis, with 5-year disease-specific survival (DSS) less than one-third in historical cohorts. However, newer therapies and combinations are associated with impressive time-to-next-treatment (TTNT), particularly allogeneic stem-cell transplantation (AlloSCT) and combination therapies notably those including extracorporeal photopheresis. In this multicentre, international study, we explored the prognostic outcomes of 178 patients exclusively managed for SS, diagnosed between 2012 and 2020, and treated in the modern therapeutic era. In this cohort, 58 different therapies were delivered, with 13.5% of patients receiving AlloSCT. Long-term survival exceeded historical reports with 5-year DSS and OS of 56.4% and 53.4% respectively. In those receiving AlloSCT, prognosis was excellent: 5-year DSS and OS were 90.5% and 78.0% respectively. Confirming the results from the Cutaneous Lymphoma International Consortium (CLIC), LDH and LCT had significant prognostic impact. Unlike earlier studies, stage did not have prognostic impact; we speculate that greater relative benefit favours patients with extensive lymphomatous nodal disease (Stage IVA2) compared to historical reports. For patients ineligible for AlloSCT, the prognosis remains relatively poor (5-year DSS 51.4% and OS 49.6%), representing ongoing unmet needs for more effective novel agents and investigation of improved therapeutic combinations., (© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)